Optimization of the therapeutic approach to patients with sarcoma: Delphi Consensus

Delphi consensus; Sarcoma treatment; Panel of expertsConsenso Delphi; Tratamiento del sarcoma; Panel de expertosConsens Delphi; Tractament del sarcoma; Panell d'expertsSoft tissue sarcomas (STS) constitute a heterogeneous group of rare solid tumors associated with significant morbidity and mortality. The evaluation and treatment of STS require a multidisciplinary team with extensive experience in the management of these types of tumors. National and international clinical practice guidelines for STS do not always provide answers to a great many situations that specialists have to contend with in their everyday practice. This consensus provides a series of specific recommendations based on available scientific evidence and the experience of a group of experts to assist in decision-making by all the specialists involved in the management of STS

Multicenter study of the seroprevalence of antibodies against covid-19 in patients with lymphoma: An analysis of the oncological group for the treatment and study of lymphomas (gotel)

The new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) coronavirus has generated a pandemic, in which there are population groups at higher risk and who are potentially fatal victims of the disease. Cancer patients have been considered a group with special susceptibility, particularly patients with lung tumour involvement and haematological neoplasms. The Spanish Lymphoma Oncology Group (GOTEL) carried out a multicenter study of SARS-CoV-2 seroprevalence in patients with lymphoma. Results: A total of 150 patients were included between 22 May and 11 June 2020. The mean age was 65 years (range 17–89), 70 women (46.5%) and 80 men (53, 5%). At the time of diagnosis of lymphoma, 13 cases were stage I (9%), 27 (18%) stage II, 37 (24.5%) stage III, and 73 (48.5%) stage IV, while 6.6% had a primary extranodal origin. A total of 10 cases with positive serology for SARS-CoV-2 were identified, which is a prevalence of 6% in this population. None of the patients required intensive care unit management and all fully recovered from the infection. Conclusion: IgG antibody seroprevalence in lymphoma patients appears similar to that of the general population and does not show greater aggressivenessThis study was supported by the European Union Horizon 2020 research and innovation programme under grant agreement number 87516

Extra-meningeal solitary fibrous tumor: an evolving entity with chameleonic morphological diversity, a hallmark molecular alteration and unresolved issues in risk stratification assessment

Solitary fibrous tumor (SFT) is a rare type of mesenchymal lesion with variable clinical presentation in which specific clinicopathologic factors have been related to patient outcome. SFT shares an important morphologic and immunohistochemical overlap with other sarcomas, hence the differential diagnosis is challenging. Although molecular studies provide significant clues, especially in the differential diagnosis with other neoplasms, a thorough hematoxylin and eosin analysis and the integration of phenotypical, clinical, and radiological features remain an essential tool in SFT diagnosis. In this review, we discuss some emerging issues still under debate in SFT

Cáncer de mama metastático estudio de serie de casos. Instituto Nacional Oncología y Radiobiología 2000-2003.

Se realizó un estudio descriptivo, retrospectivo, de las pacientes con diagnóstico de cáncer de mama metastásico atendidas en el INOR, de enero 2000 a diciembre 2003. Nuestro universo de estudio estuvo constituido por 930 pacientes con diagnóstico de cáncer de mama y la muestra de 209 pacientes con cáncer de mama metastásico. La frecuencia del cáncer de mama metastásico fue de 22,5% y el grupo de edades que predominó fue el de 50-59 años. Se observó un predominio del estadio III, tamaño tumoral T2, y afectación ganglionar de 1-3 ganglios positivos. El tipo de recaída más frecuente fue a distancia y dentro de ellas las de localización visceral, siendo el pulmón el órgano más afectado. Como primer sitio de recaída, predominaron las metástasis en partes blandas; se usó como tratamiento más frecuente la quimioterapia como modalidad única o combinada. Los resultados sugieren que, en nuestra experiencia, la incidencia de cáncer de mama metastásico fue más baja que otros reportes.  Palabras clave: Cáncer de mama, neoplasia, cáncer de mama metastásico

A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin

Predictive biomarkers of trabectedin represent an unmet need in advanced soft-tissue sarcomas (STS). DNA damage repair (DDR) genes, involved in homologous recombination or nucleotide excision repair, had been previously described as biomarkers of trabectedin resistance or sensitivity, respectively. The majority of these studies only focused on specific factors (ERCC1, ERCC5, and BRCA1) and did not evaluate several other DDR-related genes that could have a relevant role for trabectedin efficacy. In this retrospective translational study, 118 genes involved in DDR were evaluated to determine, by transcriptomics, a predictive gene signature of trabectedin efficacy. A six-gene predictive signature of trabectedin efficacy was built in a series of 139 tumor samples from patients with advanced STS. Patients in the high-risk gene signature group showed a significantly worse progression-free survival compared with patients in the low-risk group (2.1 vs 6.0 months, respectively). Differential gene expression analysis defined new potential predictive biomarkers of trabectedin sensitivity (PARP3 and CCNH) or resistance (DNAJB11 and PARP1). Our study identified a new gene signature that significantly predicts patients with higher probability to respond to treatment with trabectedin. Targeting some genes of this signature emerges as a potential strategy to enhance trabectedin efficacy.This study was funded by the Spanish Group for Research on Sarcoma (GEIS) and partially by PharmaMar. The authors would like to thank the GEIS data center for data management. The authors also thank the donors and the Hospital Universitario Virgen del Rocío—Instituto de Biomedicina de Sevilla Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT17/0015/0041) for part of the human specimens used in this study. David S. Moura is recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155)

EMBARAZO HETEROTÓPICO: PRESENTACIÓN DE UN CASO Ectopic pregnancy: Presentation of a case

El embarazo ectópico se considera por algunos autores, según su comportamiento en este decenio, como enfermedad epidémica muchas veces mortal para las mujeres que lo padecen. Nos propusimos revisar y analizar la evidencia científica disponible en la literatura mundial para determinar las manifestaciones clínicas más frecuentes delembarazo heterotópico, así como los mediosdiagnóstico más empleados en la actualidad. Se presentó un caso de embarazo heterotópico espontáneo en una paciente de 26 años de edad y 10 semanas de amenorrea. Se realizó laparotomía de urgencia y salpingectomía derecha. El embarazo intrauterino presentó una evolución favorable hasta el término. Se realizó una revisión bibliográfica actualizada acerca del embarazo heterotópico. Su tendencia actual a incrementar la incidencia en Cuba y en el mundo se atribuye a la mayor frecuencia de los factores etiopatogénicos relacionados con esta enfermedad. Se describen las formas clínicas de presentación y los métodos de diagnósticos tradicionales Se revisaron algunos aspectos de la etiología, diagnóstico y tratamiento de esta entidad.<br>Ectopic pregnancy is considered by some authors, according to its behaviour in this decennium, as an epidemic disease sometimes mortal for women who suffer it. We proposed to review and analyze the scientific evidence available in the world literature for determining clinical manifestations most frequent in heterotopic pregnancy as well as diagnostic means widely used in current times. A case of spontaneous heterotopic pregnancy was presented in a 26 year old patient with amenorrhea: 10 weeks. Emergency laparotomy and right salpingectomy were performed. The intrauterine pregnancy continued successfully to term. An updated bibliographic review of heterotopic pregnancy was made. It is an important topic and its current trend towards the increase of its incidence in Cuba and in the world is attributed to the higher frequency of the etiopathogenic factors related to this disease. The clinical forms of presentation and the traditional diagnostic methods are described. Some aspects of the etiology, diagnosis and treatment of this entity were reviewed

Cáncer de mama metastático estudio de serie de casos: Instituto Nacional Oncología y Radiobiología 2000-2003 Cancer of breast metastático study of series of cases: National institute Oncology and Radiobiología 2000-2003

Se realizó un estudio descriptivo, retrospectivo, de las pacientes con diagnóstico de cáncer de mama metastásico atendidas en el INOR, de enero 2000 a diciembre 2003. Nuestro universo de estudio estuvo constituido por 930 pacientes con diagnóstico de cáncer de mama y la muestra de 209 pacientes con cáncer de mama metastásico. La frecuencia del cáncer de mama metastásico fue de 22,5% y el grupo de edades que predominó fue el de 50-59 años. Se observó un predominio del estadio III, tamaño tumoral T2, y afectación ganglionar de 1-3 ganglios positivos. El tipo de recaída más frecuente fue a distancia y dentro de ellas las de localización visceral, siendo el pulmón el órgano más afectado. Como primer sitio de recaída, predominaron las metástasis en partes blandas; se usó como tratamiento más frecuente la quimioterapia como modalidad única o combinada. Los resultados sugieren que, en nuestra experiencia, la incidencia de cáncer de mama metastásico fue más baja que otros reportes.We performed a descriptive and retrospective trial, of a patient with diagnosis of metastatic breast cancer attended in the Oncologic National Institute of Cuba from January 2000 to December 2003. Nine hundred thirty patient with diagnosis of breast cancer and two hundred nine with metastatic breast cancer were evaluated. The frequency of the metastatic breast cancer was 22.5% and the group of ages that prevailed of 50-59 years. A prevalence of the III stage was observed, tumour size T2, and the 1-3 positive ganglions. The type of more frequent relapse was the distance and within them of visceral localization being the lung the most affected organ. The first site of relapse prevailed soft parts metastatic, using it like more frequent treatment the chemotherapy like only or combined mode. The results suggest that, in our experience, the incidence of Metastatic breast cancer was lower than in other reports